

**AMENDMENT TO RULES COMMITTEE PRINT 115–
70**

OFFERED BY MR. PANETTA OF CALIFORNIA

At the end of subtitle B of title XXXI, add the following new section:

1 **SEC. 31___ . ACCELERATION OF REPLACEMENT OF CESIUM**
2 **BLOOD IRRADIATION SOURCES.**

3 (a) GOAL.—The Administrator for Nuclear Security
4 shall ensure that the goal of the covered programs is elimi-
5 nating the use of blood irradiation devices in the United
6 States that rely on cesium chloride by December 31, 2027.

7 (b) PROGRAMS.—To meet the goal specified by sub-
8 section (a), the Administrator shall carry out the covered
9 programs in a manner that—

10 (1) is voluntary for owners of blood irradiation
11 devices;

12 (2) allows for the United States, subject to the
13 review of the Administrator, to pay up to 50 percent
14 of the per-device cost of replacing blood irradiation
15 devices covered by the programs;

16 (3) allows for the United States to pay up to
17 100 percent of the cost of removing and disposing

1 of cesium sources retired from service by the pro-
2 grams; and

3 (4) replaces such devices with x-ray irradiation
4 devices or other devices approved by the Food and
5 Drug Administration that provide significant threat
6 reduction as compared to cesium chloride
7 irradiators.

8 (c) DURATION.—The Administrator shall carry out
9 the covered programs until December 31, 2027.

10 (d) REPORT.—Not later than 180 days after the date
11 of the enactment of this Act, the Administrator shall sub-
12 mit to the appropriate congressional committees a report
13 on the covered programs, including—

14 (1) identification of each cesium chloride blood
15 irradiation device in the United States, including the
16 number, general location, and user type;

17 (2) a plan for achieving the goal established by
18 subsection (a);

19 (3) a methodology for prioritizing replacement
20 of such devices which takes into account irradiator
21 age and prior material security initiatives;

22 (4) in consultation with the Nuclear Regulatory
23 Commission and the Food and Drug Administration,
24 a strategy identifying any legislative, regulatory, or
25 other measures necessary to constrain the introduc-

1 tion of new cesium chloride blood irradiation devices;
2 and

3 (5) identification of the annual funds required
4 to meet the goal established by subsection (a).

5 (e) ASSESSMENT.—The Administrator shall submit
6 and assessment to the appropriate congressional commit-
7 tees by September 20, 2023, the results of the actions on
8 the covered programs, including—

9 (1) the number of replacement irradiators
10 under the covered programs;

11 (2) the life-cycle costs of the program, including
12 personnel training, maintenance, and replacement
13 costs for new irradiation devices;

14 (3) the cost-effectiveness of the covered pro-
15 grams;

16 (4) an analysis of the effectiveness of the new
17 irradiation devices technology; and

18 (5) a forecast whether the Administrator will
19 meet the goal established in subsection (a).

20 (f) DEFINITIONS.—In this section:

21 (1) The term “appropriate congressional com-
22 mittees” means—

23 (A) the Committee on Appropriations, the
24 Committee on Armed Services, and the Com-

1 committee on Energy and Commerce of the House
2 of Representatives; and

3 (B) the Committee on Appropriations, the
4 Committee on Armed Services, the Committee
5 on Energy and Natural Resources, and the
6 Committee on Health, Education, Labor, and
7 Pensions of the Senate.

8 (2) The term “covered programs” means the
9 following programs of the Office of Radiological Se-
10 curity of the National Nuclear Security Administra-
11 tion:

12 (A) The Cesium Irradiator Replacement
13 Program.

14 (B) The Offsite Source Recovery Program.

